{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T11:32:10Z","timestamp":1748518330630},"reference-count":25,"publisher":"Pharmaceutical Society of Japan","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,6,1]]},"DOI":"10.1248\/bpb.b21-00004","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T22:15:41Z","timestamp":1622499341000},"page":"816-821","source":"Crossref","is-referenced-by-count":3,"title":["Trends in Antipseudomonal Agent Use Based on the 2006 to 2015 Sales Data in Japan"],"prefix":"10.1248","volume":"44","author":[{"given":"Ai","family":"Ebisui","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Inose","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Kusama","sequence":"additional","affiliation":[{"name":"AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Koizumi","sequence":"additional","affiliation":[{"name":"AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Kawabe","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saki","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ishikane","sequence":"additional","affiliation":[{"name":"AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Yagi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Ohmagari","sequence":"additional","affiliation":[{"name":"AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Muraki","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) WHO. \u201cAntimicrobial resistance: global report on surveillance 2014.\u201d: \u2039https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/112642\/9789241564748_eng.pdf?sequence=1\u203a, accessed 13 July, 2020."},{"key":"2","unstructured":"2) Ministry of Health, Labour and Welfare. \u201cNational Action Plan on Antimicrobial Resistance (2016\u20132020).\u201d: \u2039https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-10900000-Kenkoukyoku\/0000120769.pdf\u203a, accessed 6 April, 2020."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Yamasaki D, Tanabe M, Muraki Y, Kato G, Ohmagari N, Yagi T. The first report of Japanese antimicrobial use measured by national database based on health insurance claims data (2011\u20132013): comparison with sales data, and trend analysis stratified by antimicrobial category and age group. <i>Infection<\/i>, <b>46<\/b>, 207\u2013214 (2018).","DOI":"10.1007\/s15010-017-1097-x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Mielko KA, Jab\u0142o\u0144ski SJ, Milczewska J, Sands D, \u0141ukaszewicz M, M\u0142ynarz P. Metabolomic studies of <i>Pseudomonas aeruginosa<\/i>. <i>World J. Microbiol. Biotechnol.<\/i>, <b>35<\/b>, 178 (2019).","DOI":"10.1007\/s11274-019-2739-1"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic resistance in <i>Pseudomonas aeruginosa<\/i>: mechanisms and alternative therapeutic strategies. <i>Biotechnol. Adv.<\/i>, <b>37<\/b>, 177\u2013192 (2019).","DOI":"10.1016\/j.biotechadv.2018.11.013"},{"key":"6","unstructured":"6) AMR Clinical Reference Center. \u201cNippon AMR One Health Report 2018.\u201d: \u2039https:\/\/amr-onehealth.ncgm.go.jp\/en\/\u203a, accessed 6 April, 2020."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Muraki Y, Kitamura M, Maeda Y, Kitahara T, Mori T, Ikeue H, Tsugita M, Tadano K, Takada K, Akamatsu T, Yamada T, Yamada T, Shiraishi T, Okuda M. Nationwide surveillance of antimicrobial consumption and resistance to <i>Pseudomonas aeruginosa<\/i> isolates at 203 Japanese hospitals in 2010. <i>Infection<\/i>, <b>41<\/b>, 415\u2013423 (2013).","DOI":"10.1007\/s15010-013-0440-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Umemura T, Mochizuki T, Muraki Y, Katayama T, Taki H, Ohmagari N, Yamagishi Y, Mikamo H, Mori T. Relationship of injectable antimicrobial use and rates in <i>Pseudomonas aeruginosa<\/i> by using the Anatomical Therapeutic Chemical Classification\/Defined Daily Dose System. <i>Jpn. J. Infect. Prev. Control<\/i>, <b>25<\/b>, 376\u2013382 (2010).","DOI":"10.4058\/jsei.25.376"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Muraki Y, Yagi T, Tsuji Y, Nishimura N, Tanabe M, Niwa T, Watanabe T, Fujimoto S, Takayama K, Murakami N, Okuda M. Japanese antimicrobial consumption surveillance: first report on oral and parenteral antimicrobial consumption in Japan (2009\u20132013). <i>J. Glob. Antimicrob. Resist<\/i>, <b>7<\/b>, 19\u201323 (2016).","DOI":"10.1016\/j.jgar.2016.07.002"},{"key":"10","unstructured":"10) WHO. \u201cWHO collaborating centre for drug statics methodology ATC\/DDD index2020\u201d: \u2039https:\/\/www.whocc.no\/atc_ddd_index\/\u203a, accessed 6 June, 2019."},{"key":"11","unstructured":"11) AMR Clinical Reference Center. \u201cRules for creating antibiotics master.\u201d: \u2039amrcrc.ncgm.go.jp\/surveillance\/030\/20190116rule.pdf\u203a, accessed 13 July, 2020."},{"key":"12","unstructured":"12) Statistics Bureau of Japan. \u201cPopulation estimate.\u201d: \u2039http:\/\/www.stat.go.jp\/data\/jinsui\/2016np\/index.htm\u203a, accessed 6 February, 2019."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kinoshita N, Morisaki N, Uda K, Kasai M, Horikoshi Y, Miyairi I. Nationwide study of outpatient oral antimicrobial utilization patterns for children in Japan (2013\u20132016). <i>J. Infect. Chemother.<\/i>, <b>25<\/b>, 22\u201327 (2019).","DOI":"10.1016\/j.jiac.2018.10.002"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kawabe A, Muraki Y, Inose R, Kusama Y, Goto R, Ebisui A, Ishii S, Ishikane M, Ohge H, Ohmagari N. Trends of antifungal use based on sales data in Japan from 2006 to 2015. <i>Biol. Pharm. Bull.<\/i>, <b>43<\/b>, 1248\u20131252 (2020).","DOI":"10.1248\/bpb.b20-00302"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Goto R, Inose R, Kusama Y, Kawabe A, Ishii S, Ebisui A, Ishikane M, Yagi T, Ohmagari N, Muraki Y. Trends of the use of anti-methicillin-resistant <i>Staphylococcus aureus<\/i> agents in Japan based on sales data from 2006 to 2015. <i>Biol. Pharm. Bull.<\/i>, <b>43<\/b>, 1906\u20131910 (2020).","DOI":"10.1248\/bpb.b20-00605"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Tsutsui A, Yahara K, Shibayama K. Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016. <i>J. Infect. Chemother.<\/i>, <b>24<\/b>, 414\u2013421 (2018).","DOI":"10.1016\/j.jiac.2018.01.003"},{"key":"17","unstructured":"17) European Centre for Disease Prevention and Control. \u201cTrend of antimicrobial consumption by country.\u201d: \u2039https:\/\/www.ecdc.europa.eu\/en\/antimicrobial-consumption\/database\/trend-country\u203a, accessed 6 April, 2020."},{"key":"18","unstructured":"18) European Centre for Disease Prevention and Control. \u201cAntimicrobial Resistance Surveillance in Europe 2015.\u201d: \u2039https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/media\/en\/publications\/Publications\/antimicrobial-resistance-europe-2015.pdf\u203a, accessed 6 April, 2020."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Willby M, Sikes RD, Malik S, Metchock B, Posey JE. Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in <i>Mycobacterium tuberculosis.<\/i> <i>Antimicrob. Agents Chemother.<\/i>, <b>59<\/b>, 5427\u20135434 (2015).","DOI":"10.1128\/AAC.00662-15"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Niwa T, Shinoda Y, Suzuki A, Ohmori T, Yasuda M, Ohta H, Fukao A, Kitaichi K, Matsuura K, Sugiyama T, Murakami N, Itoh Y. Outcome measurement of extensive implementation of antimicrobial stewardship in patients receiving intravenous antibiotics in a Japanese University Hospital. <i>Int. J. Clin. Pract.<\/i>, <b>66<\/b>, 999\u20131008 (2012).","DOI":"10.1111\/j.1742-1241.2012.02999.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Liang SY. Sepsis and other infectious disease emergencies in the elderly. <i>Emerg. Med. Clin. North Am.<\/i>, <b>34<\/b>, 501\u2013522 (2016).","DOI":"10.1016\/j.emc.2016.04.005"},{"key":"22","unstructured":"22) European Association of Urology. \u201cEAU Guidelines on Urological Infections.\u201d: \u2039https:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-on-Urological-infections-2019.pdf\u203a, accessed 19 May, 2020."},{"key":"23","unstructured":"23) Mikasa K, Aoki N, Aoki Y, Abe S, Iwata S, Ouchi K, Kasahara K, Kadota J, Kishida N, Kobayashi O, Sakata H, Seki M, Tsukada H, Tokue Y, Nakamura-Uchiyama F, Higa F, Maeda K, Yanagihara K, Yoshida K. The JAID\/JSC guideline to clinical management of infectious diseases (respiratory infections). <i>Kansenshogaku Zasshi<\/i>, <b>88<\/b>, 1\u2013109 (2014)."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Baditoiu L, Axente C, Lungeanu D, Muntean D, Horhat F, Moldovan R, Hogea E, Bedreag O, Sandesc D, Licker M. Intensive care antibiotic consumption and resistance patterns: a cross-correlation analysis. <i>Ann. Clin. Microbiol. Antimicrob.<\/i>, <b>16<\/b>, 71 (2017).","DOI":"10.1186\/s12941-017-0251-8"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Campos J, Ferech M, L\u00e1zaro E, de Abajo F, Oteo J, Stephens P, Goossens H. Surveillance of outpatient antibiotic consumption in Spain according to sales data and reimbursement data. <i>J. Antimicrob. Chemother.<\/i>, <b>60<\/b>, 698\u2013701 (2007).","DOI":"10.1093\/jac\/dkm248"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/6\/44_b21-00004\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T05:08:19Z","timestamp":1622869699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/6\/44_b21-00004\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b21-00004","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]}}}